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Abstract
Background: During the onset of an inflammatory response signaling pathways are activated for ‘‘translating’’ extracellular
signals into intracellular responses converging to the activation of nuclear factor (NF)-kB, a central transcription factor in
driving the inflammatory response. An inadequate control of its transcriptional activity is associated with the culmination of a
hyper-inflammatory response making it a desired therapeutic target. Predicated upon the nature of the response, a systems
level analysis might provide rational leads for the development of strategies that promote the resolution of the response.
Methodology and Findings: A physicochemical host response model is proposed to integrate biological information in the
form of kinetic rules and signaling cascades with pharmacokinetic models of drug action for the modulation of the response.
The unifying hypothesis is that the response is triggered by the activation of the NFkB signaling module and corticosteroids
serve as a template for assessing anti-inflammatory strategies. The proposed in silico model is evaluated through its ability to
predict and modulate uncontrolled responses. The pre-exposure of the system to hypercortisolemia, i.e. 6 hr before or
simultaneously with the infectious challenge ‘‘reprograms’’ the dynamics of the host towards a balanced inflammatory
response. However, if such an intervention occurs long before the inflammatory insult a symptomatic effect is observed
instead of a protective relief while a steroid infusion after inducing inflammation requires much higher drug doses.
Conclusions and Significance: We propose a reversed engineered inflammation model that seeks to describe how the
system responds to a multitude of external signals. Timing of intervention and dosage regimes appears to be key
determinants for the protective or symptomatic effect of exogenous corticosteroids. Such results lie in qualitative
agreement with in vivo human studies exposed both to LPS and corticosteroids under various time intervals thus improving
our understanding of how interacting modules generate a behavior.
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Introduction
The systemic inflammatory response syndrome (SIRS) often
accompanies critical illnesses and can be an important cause of
morbidity and mortality [1]. It is evoked by many stimuli including
infection, trauma, invasive surgery and biological stressors in
general and is characterized by a cascade of events during which
multiple cell types are deployed to locate pathogens, recruit cells
and eventually eliminate the offenders and restore homeostasis.
Under normal circumstances, the dynamics of an acute inflam-
matory response are tightly regulated [2]; however when anti-
inflammatory processes fail an amplified inflammation can turn
what is normally a beneficial reparative process into a detrimental
physiological state which is characterized by severe, uncontrolled
systemic inflammation and multiple organ dysfunction [3].
Despite our growing understanding of the cellular and
molecular mechanisms of SIRS [4] and the success of pre-clinical
studies, not many effective therapies exist [5,6,7,8,9,10,11,12,13].
A key reason for this conundrum is the difficulty in predicting how
the complex dynamics of inflammation are modulated. Since
successful interventions depend on the stage and trajectory of the
response, systems-oriented approaches have been advocated for
the control of physiological responses [14]. Thus, significant
opportunities emerge in the context of systems biology which aims
at the deconvolution of complex phenomena, such as the
inflammatory response, to their constitutive elements and the
quantification of the dynamic interactions among these elements
through appropriate computational models. Mathematical models
integrating the interacting elements of the inflammatory response
offer the opportunity to establish causal relationships and evaluate
putative intervention strategies [15].
A number of excellent prior studies [16,17,18,19,20,21] have
placed emphasis on simulating inflammation based on the kinetics
of well-defined markers [22,23]. The key characteristic of these
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4706models is the a priori postulation of specific components (cytokines
etc.) that are consistent with prior biological knowledge.
Appropriate interactions between components and their associated
dynamics are subsequently evaluated. In an attempt to integrate
high-throughput transcriptional data we recently introduced a
systems level approach [24,25] that decomposes high-dimensional
microarray data into a critical set of dynamic features that are
considered to be the elementary inflammatory responses triggered
by an endotoxin stimulus in peripheral blood leukocytes (PBLs).
Our fundamental assumption is that the transcriptional signatures
capture the cellular dynamics in response to the inflammatory
agent. These constitutive dynamics features are considered to be
the ‘‘blueprints’’ of the orchestrated dynamics of the perturbed
biological system and in order to study the underlying complexity
of an in vivo human response to endotoxin a semi-mechanistic
indirect response model was proposed in [26]. Our approach
couples receptor mediated phenomena with transcriptional effects
based on ligand-receptor kinetics. One of the key assumptions
underpinning our prior modeling effort is that intracellular
signaling cascades activating inflammation-specific transcriptional
responses can be mathematically approximated by an aggregate
variable serving as a proxy of the activating signal. However,
during the onset of an inflammatory response signaling pathways
are activated for ‘‘translating’’ extracellular signals into intracel-
lular responses [27]. Such a signal transduction cascade converges
to the activation of effector proteins (transcription factors) that
regulate the expression of critical genes. Therefore, understanding
more about the complex inflammatory reactions would require the
development of computational models that incorporate biological
information in the form of critical signaling cascades and kinetic
rules. We wish therefore to deconvolute and interpret the
combined activating signal with its ‘‘mechanistic’’ equivalence
developing more interpretable and biologically relevant systems
based models of inflammation.
The work to be discussed in this paper aims to address the
possibility of a semi-mechanistic host response model that
integrates signaling and pharmacokinetic models of drug action
for the modulation of the inflammatory response. We opt therefore
to develop a reverse-engineered model of endotoxin-induced
human inflammation that couples elementary signaling pathways
with pharmacokinetic models of corticosteroids, as putative
controllers of the inflammatory response. Nuclear factor (NF)-kB
is a central transcription factor that plays a major role in driving
the inflammatory response [28]. We test the hypothesis that the
activation of NFkB signaling module serves as the representative
signaling controller of the pro-inflammatory genetic switch
underpinning the manifestation of transcriptional responses. An
inadequate control of its transcriptional activity is associated with
the culmination of a hyperinflammatory response making it a
desired therapeutic target. Anti-inflammatory drugs such as
corticosteroids play a critical role in modulating the progression
of inflammation interfering either transcriptionally with the
activity of NF-kB [29,30] or priming anti-inflammatory cytokines
such as IL-10 [31]. Effectively, the dynamic integration of
regulatory signaling information with the anti-inflammatory effect
of corticosteroids, , sheds some light on how the system responds to
a multitude of external signals offering the possibility of
performing in silico experiments that would eventually allow us
to rationalize the success/failure of particular interventions. It is
the ultimate goal of this study to trace the non-linear inflammatory
signal more efficiently thus improving our understanding of how
interacting modules respond to generate a behavior. The proposed
integrated model of systemic inflammation prior to any interven-
tion is characterized by the dynamic state of eleven (11) variables
that describe the propagation of LPS signaling through interacting
modules. Its evaluation is demonstrated through a series of
biologically relevant scenarios indicative of the non-linear
dynamics of inflammation. These scenarios involve the implica-
tions of increased host susceptibility to endotoxin stimulus followed
by systematic perturbations in the regulatory signaling module.
Simulating the trajectory of an unconstrained inflammatory
response allows us to perform computational tests for the
therapeutic evaluation of corticosteroid based intervention strat-
egies. The corticosteroid intervention envelope consists of five (5)
deterministic equations that take drug binding interactions into
account seeking to describe the elementary reactions of the cellular
signaling of steroids. The pre-exposure of the system to
hypercortisolemia, i.e. 6 hr before or simultaneously with the
main endotoxin challenge ‘‘reprograms’’ the intrinsic dynamics of
the host towards a balanced (suppressed) inflammatory response.
However, if such an intervention occurs long before LPS (i.e.
12 hr or 144 hr) a symptomatic effect is observed instead of a
protective relief while a steroid infusion after inducing inflamma-
tion requires much higher drug doses. Therefore, timing of
intervention and dosage regimes appears to be key determinants
for the protective or symptomatic effect of exogenous corticoste-
roids on the progression of inflammation. Qualitatively, such in
silico results lie in agreement with in vivo human studies exposed
both to LPS and corticosteroids under various time intervals thus
paving the way for improving the working feedback loop between
‘‘dry’’ and ‘‘wet’’ experiments.
Results
Qualitative assessment of NFkB-dependent indirect
response model of systemic inflammation
We have previously demonstrated that the transcriptional
dynamics of human leukocytes exposed to bacterial endotoxin
can be decomposed into to three elementary comprehensive
responses [24,26]. Unlike previous approaches that concentrate on
specific biomarkers, these elementary responses capture the
functional dynamics and were shown to be related to pro-
inflammatory (P), anti-inflammatory (A) and energetic (E)
transcriptional events associated with the overall host response.
The response is triggered by the activation of the NFkB signaling
module as a result of the formation of an activating signal
associated with the binding of LPS to appropriate receptors. We
hypothesize that NFkB serves as a proxy for the inflammation
specific transcription factors that initiates the expression of pro-
inflammatory genes while its activity is primarily modulated by the
kinase activity (IKK) and the inhibitor (IKBa). In this study, we
seek to describe the host response to endotoxin via interacting
modules that involve the propagation of LPS signaling on the
transcriptional response level through NFkB dependent mecha-
nism and the genomic signaling of exogenous corticosteroids, as
the putative controllers of inflammation. The corticosteroid
intervention envelope consists of a set of elementary interactions
that involve: (i) the binding of the corticosteroid drug (D) to its
cytosolic receptor (GR), (ii) the subsequent formation of the drug-
receptor complex (DR) (iii) the translocation of the cytosolic
complex to the nucleus (DR(N)) that alters the transcriptional
machinery activating or repressing numerous genes and finally (iv)
the autoregulation of the gene transcript of the glucocorticoid
receptor (Rm). All the interacting components and modules that
constitute the NFkB dependent physicochemical model of
inflammation are shown in Figure 1.
Kinetic parameters are estimated in order to best reproduce the
essential transcriptional responses associated with experimental
Physicochemical Model
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associated with a self-limited inflammatory response, of the major
transcriptional signatures coupled with the elementary signaling
molecules of NF-kB pathway are presented in Figure 2. In essence,
a self-limited inflammatory response involves the successful
elimination of the inflammatory stimulus within the first 2 hr
post-endotoxin administration while followed by a subsequent
resolution within 24 hr. We assess the appropriateness of the
structure of the proposed model by simulating a malfunction in the
clearance rate of pathogen-derived endotoxin, Figure 3. Such a
case is simulated by manipulating (decreasing) the parameter
associated with the degradation rate of LPS, kLPS,2. Although
decreased degradation of LPS is not associated with a defined
clinical condition it is possible that this phenomenon may exist.
For example, it is known that triglyceride-rich lipoproteins bind to
LPS and that these complexes are cleared by binding to
lipoprotein receptors. Furthermore, these receptors are abundant
in the liver which clears ,70% of lipoproteins from the
Figure 1. Schematic illustration of a reverse engineered model of systemic inflammation. Interacting modules involve the propagation of
LPS signaling on the transcriptional response level coupled with the anti-inflammatory effect of corticosteroids. The propagation of LPS signaling
involves the interaction of the inflammatory stimulus, LPS with its receptor (R) forming the surface complex (LPSR) which activates IKK activity. The
IKK-dependent signal activates the translocation of NF-kB (NFkBn) through phosphorylation and degradation of its primary inhibitor, IkBa. The nuclear
NFkB (NFkBn) is auto-regulated by its inhibitor protein, IKBa and stimulates the production rate of the pro-inflammatory response (P) while there is
certain connectivity among the essential transcriptional signatures (P, A, E). The mRNA of the receptor (mRNA,R) is stimulated by pro-inflammation (P)
and it is translated to the surface protein (R). The corticosteroid intervention envelope consists of the corticosteroid drug (D) which binds to its
intracellular receptor (GR) forming the cytosolic complex (DR) that translocates to the nucleus (DR(N)) and modulates the dynamics of inflammation
via an upregulation of anti-inflammatory proteins (IkBa, A). The nuclear complex (DR(N)) auto-regulates the transcription of its receptor (GR) and a
portion of nuclear receptor DR(N) is recycled. The potentiating effect of DR(N) to A is represented by dashed lines as in silico results refer to
corticosteroid perturbations on IKBa. Qualitatively, similar results are observed if the mode of action involves upregulation of the anti-inflammatory
response (A).
doi:10.1371/journal.pone.0004706.g001
Physicochemical Model
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dysfunction may have impaired clearance of LPS. As shown in
Figure 3 the inflammatory stimulus persists and leads to an
aberrant NFkB activity that drives downstream a chronic
inflammatory response. We further evaluate the proposed in silico
model by exploring the possibility of a mechanistic maladaption in
the dynamics of the regulatory NFkB signaling module. As
illustrated in Figure 4, performing an in silico IkBa
2/2 knock-out
experiment we simulate a sustained inflammatory response that
fails to resolve. Another mode of perturbation of the underlying
dynamics of the probed system is related to the presence of a
‘‘prior’’ insult that coupled with the LPS stimulus account for an
overwhelming production of pro-inflammatory mediators,
Figure 5. Such a sustained pro-inflammatory signaling deregulates
the NFkB signaling module leading to a persistent NFkB activity.
Such persistence implies that the nuclear concentration of NFkB
cannot be further constrained by its primary inhibitor, IkBa and
eventually settle to a steady state far away from their equilibrium
(homeostasis). We simulate such a scenario by manipulating the
zero order production rate of the pro-inflammatory response
(Kin,P) and particularly increasing it twice its initial value.
Modulating the progression of an unresolved
inflammatory response
The in silico model of inflammation enables us to predict an
inflammatory response that does not properly abate making it a
critical enabler for the evaluation of corticosteroid-based inter-
vention strategies. Characteristic dynamics of the profiles of the
signaling molecules that constitute the corticosteroid intervention
envelope are presented in Figure 6. An intravenous injection of the
drug, via the activation of intermediate signaling steps, eventually
leads to the up-regulation of the active complex, DR(N). Based on
the mode of corticosteroids action defined, to be discussed in
detailed in the Methods section, we explore the potential of the
active signal, DR(N)norm, in modulating the progression of an
unresolved inflammation, Figure 7. We observe that such a signal
mediates the corticosteroid effect on the transcriptional response
level primes the dynamic state of NFkB inhibitor so that it suffices
to promote resolution of the inflammatory response. Despite the
high initial LPS concentration which perturbs the dynamics of
inflammation (dashed lines), the corticosteroid intervention in the
form of an intravenous (i.v.) injection initiated at t=0 hr
‘‘reprograms’’ the dynamic state of the system in favor of a
Figure 2. Estimation of relevant model parameters. Temporal profiles of the elements that constitute the NFkB dependent model of
endotoxin-induced inflammation. Solid lines (-) correspond to model predictions whilst the symbols (N) denote for the experimentally measured
transcriptional signatures.
doi:10.1371/journal.pone.0004706.g002
Table 1. Estimated values of the parameters based on self-limited response data.
Parameter Value Parameter Value Parameter Value Parameter Value
kLPS,1 4.500 kin,mRNA,R 0.090 kI,2 0.870 kP,R 1.740
kLPS,2 6.790 kout,mRNA,R 0.250 Kin,P 0.030 kP,1 29.740
ksyn 0.020 kNFkB,1 16.290 Kout,P 0.330 kP,2 9.050
k1 3.000 kNFkB,2 1.180 Kin,A 0.090 kA,1 0.010
k2 0.040 Kin,IKBa 0.460 Kout,A 0.590 kA,E 5.300
k3 5.000 kIkBa,1 13.270 Kin,E 0.080 kE,P 2.210
k4 2.240 kI,1 1.400 Kout,E 0.280
The values for k1 and k2 are taken from [75].
doi:10.1371/journal.pone.0004706.t001
Physicochemical Model
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solid lines in Figure 7 we observe that the intervention strategy
plays a critical role in the dynamics of IkBa during the first 4 hrs
post-LPS where suffices to control the intrinsic inflammmatory
dynamics favoring homeostasis within 24 hrs. On the other hand,
prior to any intervention the system seems to have lost any
potential for attenuation and its inability to adapt to high LPS
concentration is mathematically translated into unconstrained
responses (dashed lines). Therefore, the intervention envelope
based on corticosteroids serves as a critical enabler to explore the
capability of different intervention strategies in modulating the
progression of systemic inflammation. Another illustration of the
protective effect of corticosteroids is shown in Figure 8. We
simulate a continuous infusion of the steroid drug that is initiated
at t=0 hr (simultaneously with LPS) and continues for 6 hr post-
LPS administration (CORT-LPS strategy). As seen in Figure 8
such treatment strategy suffices to reverse the deleterious outcome
of a persistent non-infectious inflammatory response (high initial
LPS concentration). Moreover, pre-exposing the system before
endotoxin challenge for 6 hr to hypercortisolemia we observe a
proper modulation on the progression of the inflammatory
response as well, Figure 9. The corticosteroid intervention occurs
at t=26 hr followed by the concomitant administration of the
endotoxin stimulus at t=0 hr and the infusion continues for 6 hr
after the endotoxin challenge. In addition, similar responses are
observed for the system if it is pre-exposed to hypercortisolemia for
6 hr but the steroid intervention is initiated at t=212 hr (CORT-
6-LPS), Figure 10. However, if the system is pre-exposed to
Figure 3. Temporal responses of model elements in a persistent infectious inflammatory response. Reducing the degradation rate of
LPS to half of its initial value we simulate the case of an unsuccessful clearance of LPS that accounts for the sustained (aberrant) activity of NFkB
leading to a chronic inflammatory response.
doi:10.1371/journal.pone.0004706.g003
Figure 4. Simulation of a knock-out in silico experiment (IkBa
2/2). Manipulating the model so that there is no de novo transcriptional
synthesis of NF-kB inhibitor (IkBa) which is responsible for the absence of NF-kB auto-regulatory feedback loop. Such a scenario accounts for
maladapted activity of NFkBn that triggers an uncompensated inflammatory response.
doi:10.1371/journal.pone.0004706.g004
Physicochemical Model
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(6 hr) but the time interval between the termination of infusion
and LPS administration is greater (12 h), Figure 11, we observe a
blunted effect of the corticosteroid treatment on the progression of
inflammation (Cort-12-LPS). Similar results are obtained if the
system is exposed to a continuous infusion of hypercortisolemia
initiated at t.0 hr after the administration of endotoxin (i.e.
t=1 hr), dashed lines in Figure 12. On the other hand, as shown
in Figure 12 the progression of the inflammatory response is
differently perturbed on a dose-dependent manner (dashed lines
versus solid). Preserving the route of drug administration the active
signal DR(N) must increase in magnitude in order for the system to
respond to a multitude of external signals (LPS, Drug).Therefore,
dose-dependent profiles are simulated in Figure 12 and Figure 13
where there exists a dosage regime that modulates the dynamics of
the system towards resolution.
Discussion
Malfunction in LPS’s clearance rate
The dynamics of the inflammatory response are highly complex
such that a maladaption in the homeostasis of the system can be
attributed to various reasons. One such possibility is associated with
a malfunction in endotoxin clearance rate which corresponds to a
higher exposure of the host to the stimulus. In Figure 3 we simulate
the case of a persistent inflammatory response which corresponds to
an increased exposure of the host response to the inflammatory
stimulus (LPS). As shown in Figure 3, the inferred NFkB activity can
Figure 5. Pre-existence of pro-inflammatory mediators may enhance abnormally the intracellular signaling through IKK. Such a
response leads to an unconstrained activity of NFkBn that drives downstream a persistent pro-inflammatory response which cannot be counter-
regulated by the anti-inflammatory arm of the host defense system. Such a mode of dysregulation is simulated by manipulating the zero production
rate of pro-inflammation (Kin,P) so that Kin,P(unhealthy response) ,2* Kin,P (healthy response).
doi:10.1371/journal.pone.0004706.g005
Figure 6. Dynamic evolution of model elements that constitute the mechanistic pharmacokinetic model of corticosteroids action
given the parameters and initial conditions extracted from [52].
doi:10.1371/journal.pone.0004706.g006
Physicochemical Model
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to the inflammatory stimulus while trying to adapt its regulatory
activity at 2–3 hr post-endotoxin administration. However, at
t.3 hr the activity of NFkB cannot be regulated successfully and it
settles to a sustained elevated state that drives downstream the over-
excitation of both pro- and anti-inflammatory mediators; leading to
an unconstrained inflammatory response. Interestingly, in [32]
Klinke et al. aim at exploring experimentally the possibility of
modulating the temporal controlof NF-kB activation. Macrophages
are exposed to a persistent inflammatory stimulus (LPS) and the
available experimental data show the presence of a ‘‘damped’’
oscillatory behavior in NF-kB activity.
Maladaption in the dynamics of NFkB signaling module
The protein inhibitor of NF-kB (IkBa) aims at retrieving nuclear
concentration of NF-kB with the formation of an inactive complex
in the cytoplasm regulating the expression of various inflammatory
genes. The transcription factor NF-kB up-regulates the gene
transcript of IkBa (mRNA,IkBa) so that the translated protein IkBa
serves as the major component for regulating its transcriptional
activity.. Thus, in Figure 4 we simulate the case of no
transcriptional activity of NF-kB in the promoter region of IkBa.
In the absence of NF-kB inhibitor (IkBa
2/2) there is an aberrant
regulatory activity of NF-kB that leads to its persistent nuclear
activity driving an inflammatory response that fails to restore
Figure 7. Exploring the mode of corticosteroid action in enhancing the transcriptional synthesis of IkBa which is illustrated by the
solid arrow. An i.v. injection of the corticosteroid drug administered concomitantly with endotoxin (tin=0 hr) suffices to reverse (prevent) the lethal
effect of a high dose of endotoxin. Solid lines (-) correspond to the inflammatory resolution due to the corticosteroid infusion at t=0 hr while dashed
lines (--) simulate the progression of inflammation in response to a high concentration of LPS (i.e. LPS(t=0 hr)=4).
doi:10.1371/journal.pone.0004706.g007
Figure 8. Exploring the effect of corticosteroids on CORT-LPS group. The drug is administered as a continuous infusion initiated
simultaneously with LPS administration (tin=0 hr) for 6 hr (tstop=6 hr) and we observe a resolution in the progression of inflammation.
doi:10.1371/journal.pone.0004706.g008
Physicochemical Model
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annotating the impact of such a knock out in inducing a chronic
inflammatory response [33].
Additionally a pre-existence of pro-inflammatory cytokines due
to the presence of a prior ‘‘insult’’ may deregulate the intracellular
dynamics responsible for an amplification of the inflammatory
response, Figure 5. In our model such a scenario can be simulated
due to the positive feedback interaction between the intracellular
critical node (IKK activity) and the pro-inflammatory response
that disturbs the bistable behavior of the system. Therefore we
attempt to manipulate (increase) the zero order production rate of
the essential pro-inflammatory signaling. Clinically, such an
increased rate in the production of pro-inflammatory mediators
might be the outcome of a surgical trauma followed by bacterial
infection, a so called two hit scenario [34].
Evaluating the corticosteroid intervention envelope in
modulating the progression of systemic inflammation
Due to the physiological role of corticosteroids in the immune
system [29] researchers have put significant effort in understand-
ing the cytokine dynamics under hypercortisolemia
[35,36,37,38,39,40]. These studies have focused on elucidating
the in vivo responses to endotoxin (LPS) when there is an exposure
of subjects to hypercortisolemia for various durations of time.
Figure 9. Hypercortisolemia for 6 hr prior to LPS challenge (tin=26 hr). The system is pre-exposed for 6 hr to a continuous infusion of
corticosteroids while it is continued for another 6 hr after the endotoxin challenge (tstop=6 hr). Such an intervention ‘‘reprograms’’ the dynamics of
the system modulating the effect of a high LPS concentration.
doi:10.1371/journal.pone.0004706.g009
Figure 10. Exploring the effect of a continuous infusion of corticosteroids for 6 hr initiated at 12 hr prior to LPS (tin=212 hr) and
elapsed at t=26 hr before the administration of the inflammatory stimulus (LPS), (CORT-6-LPS). Such hypercortisolemia modulates
significantly the progression of a systemic inflammatory response syndrome.
doi:10.1371/journal.pone.0004706.g010
Physicochemical Model
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ticoid infusion concurrent with and before the endotoxin
challenge. The hydrocortisone infusion lasted for a 6 hr period
with subsequent intervening periods of 6 (CORT-6-LPS), 12
(CORT-12-LPS) and 144 hr (CORT-144-LPS) before endotoxin
administration or simultaneously with LPS challenge (CORT-
LPS). Experimental measurements of cytokines and hemodynamic
parameters suggest the integral role of hypercortisolemia in
CORT-LPS and CORT-6-LPS groups in modulating the cytokine
network characterized by decreased plasma concentrations of
various cytokines, i.e. TNF, IL-6 when compared to the group that
received only LPS. However, in CORT-12-LPS and CORT-144-
LPS the plasma concentrations of the aforementioned inflamma-
tory mediators were significantly increased compared to CORT-
LPS and CORT-6-LPS groups. Therefore, such evidence suggest
the critical impact of the duration of the corticosteroid
intervention before inducing inflammation in perturbing the
dynamics of both hormonal and cytokine level.
Herein, we explore the capability of corticosteroids to modulate
the inflammatory response under various treatment schedules. As
shown in Figure 7 a single i.v. injection of corticosteroids at
t=0 hr suffices to reverse the dynamics in response to the high
concentration of LPS. Similar results were obtained if we
preserved the timing of intervention but modified the route of
drug administration switching to a continuous infusion, Figure 8.
Moreover, if the system is pre-exposed to hypercortisolemia for
6 hr and concomitantly with LPS the hypercortisolemia is
continued for another 6 hr, Figure 9, the intrinsic dynamics of
the system were effectively modulated as well. Such results support
an early intervention strategy that targets the regulatory arms of
systemic inflammation and successfully capture the dynamic
behavior of the system in CORT-LPS and CORT-6-LPS groups
of the aforementioned experimental study. Complementary to this,
in [41] there is emphasis on the potential of a preoperative
administration of corticosteroids in alleviating surgical stress. The
underlying hypothesis of such a preoperative exposure stems from
the fact that a modification of the inflammatory dynamics at an
early stage (transcriptional level) would seem to be beneficial in
balancing the immune response given that these anti-inflammatory
drugs (corticosteroids) inhibit pro-inflammatory transcription
factors (NF-kB).
However, as previously stated, if the corticosteroid intervention is
terminated 12 h or 6 days before the administration of LPS the
dynamics of the cytokine network are quite different. In order to
simulate such a scenario we explore the potential of a continuous
infusion of steroids that is terminated 12 h before the endotoxin
challenge. As seen in Figure 11 such an intervention strategy fails to
reverse the effects of a high concentration of LPS. Similar results are
observed if the intervention strategy elapses at times greater than
12 hr from LPS administration (data not shown here). The primary
reason for such a failure stems from the fact that at t.9h rt h e
transcriptional profile of IkBa is resolved. Therefore any pre-
exposure to corticosteroid infusion that is terminated at t.9h r
would not ‘‘reprogram’’ the inflammatory dynamics towards a
reversal in the progression rate of an inflammatory response. In
addition to this,exploring the responseof the system at laterstagesof
the progression of the inflammatory response, Figure 12, the active
steroid signal, DR(N)norm, has to increase in magnitude in order for
the inflammatory response to be tightly regulated. These in silico
results lie in agreement with studies [31] that suggest a dose-
dependent decrease in LPS-induced TNF in peripheral human
blood leukocytes that are exposed to hydrocortisone infusion. A
discrepancy between the experimental evidence in [31] and our in
silico results is related to the concentration of the anti-inflammatory
cytokine IL10. In particular, van der Poll and Lowry [31]
demonstrate increased plasma concentrations of IL10 at higher
corticosteroid doses. In our model, due to our hypothesis that the
drug stimulates the transcription rate of IkBa, it is expected to
observe the solid trajectories of Figure 12 which simulate decreased
inflammatory responses (P, A, E). If we assume that corticosteroids
instead of up-regulating the inhibitor of NFkB they prime the
production rate of IL10 signaling (A), Figure 12 is extended to
Figure 13. As shown in Figure 13 the gradual increase in the anti-
inflammatory (A) signaling as the drug dose increases modulates the
response of the system towards a more balanced inflammatory
response. In addition, the computational experiments presented in
Figure 11. Pre-exposure the system into hypercortisolemia which is initiated as a continuous infusion 18 hr before the endotoxin
challenge (tin=218 hr) and continued for 6 hr (tstop=212 hr), (CORT-12-LPS). Such intervention strategy does not have a profound effect
in the dynamic state of the system while the progression of an unresolved inflammation (solid lines) continues after the termination of steroid
infusion.
doi:10.1371/journal.pone.0004706.g011
Physicochemical Model
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corticosteroid intervention envelope perturbs the state of the anti-
inflammatory (A) signaling which lie in agreement with the
pleiotropic mode of corticosteroids anti-inflammatory activity.
Despite the controversies regarding the administration of either
high-dose steroids for the short-term in septic patients [42] or the
prolonged use of low dose steroids in clinical settings [43] the present
study provides qualitative insight on how the system responds to
various intervention strategies opening challenging windows towards
the design of effective drug treatment schedules [44].
In summary we have developed a semi-mechanistic host
response model that describes the dynamic evolution of an in vivo
human response to endotoxin. Interacting components involve
elementary signaling pathways that propagate extracellular signals
to the transcriptional response level and pharmacokinetic models
of corticosteroids, as putative controllers of the inflammatory
response. Model parameters are appropriately evaluated so that to
reproduce a self-limited inflammatory response that resolves
within 24 hr post-endotoxin administration. The potential of the
model is demonstrated via computational tests performed to
reproduce biologically relevant scenarios associated with an
increase in host’s susceptibility to endotoxin stimulus as well as
in the regulatory interactions of signaling cascades. Exploring the
possible effects of systemic perturbations enables us to trace the
dynamics of a systemic inflammatory response syndrome. In silico
experiments that activate the corticosteroid intervention envelope
in order to modulate the progression of inflammation, encourage
the proper design of intervention strategies that target early arms
of the host response modulating the activity of crucial pro-
inflammatory transcription factors. Such a modeling framework
can potentially offer significant insight as to how a host undergoing
an inflammatory response responds to a multitude of external
signals through interacting signaling modules and possible
strategies for restoring homeostasis. The work discussed in this
study lays the foundation for an in silico ‘‘disease’’ progression
model that sheds light on the nature of disease and how it responds
to pharmacological interventions which is central to translational
systems biology [45,46].
Figure 12. Dose-dependent modulation in the progression of the inflammatory response due to corticosteroids initiating infusion
at t=1 hr and for 6 hr post-endotoxin administration at multiple doses (D0). The solid arrow illustrates the mode of corticosteroid action
via up-regulation of mRNA,IkBa. Solid lines (-) characterize a resolution in the inflammatory response while dashed lines (--) and dotted (…)
correspond to lower drug doses that does not regulate properly the aberrant activity of NFkB if the intervention is initiated after the endotoxin
challenge. The DR(N) profile that corresponds to the lower drug dose, D0=20 ng/mL, constitutes the basis active signal normalized to (0,1) values,
while the active signals for larger doses are scaled with respect to the lowest drug dose.
doi:10.1371/journal.pone.0004706.g012
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Human endotoxin model and data collection
The data used in this study were generated as part of the
Inflammation and Host Response to Injury Large Scale
Collaborative Project funded by the USPHS, U54 GM621119
[47,48]. Human subjects were injected intravenously with
endotoxin (CC-RE, lot 2) at a dose of 2-ng/kg body weight
(endotoxin treated subjects) or 0.9% sodium chloride (placebo
treated subjects). Following lysis of erythrocytes and isolation of
total RNA from leukocyte pellets, [47], biotin-labeled cRNA was
hybridized to the Hu133A and Hu133B arrays containing a total
of 44,924 probes for measuring the expression level of genes that
can be either activated or repressed in response to endotoxin. A set
of 5,093 probe sets were characterized by significant variation
(corresponding to 0.1% false discovery rate) across the time course
of the experiment using the SAM software [49]. The data are
publicly available through the GEO Omnibus Database (http://
www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE3284. The data have been appropriately de-identified, and
appropriate IRB approval and informed, written consent were
obtained by the glue grant investigators [47].
An indirect response model of human endotoxin-
induced inflammation
In the proposed model, the inflammatory response is activated
when endotoxin is recognized by pathogen recognition receptors
[50]. Such recognition process involves the induction of a signal
transduction cascade that triggers downstream critical signaling
modules for the activation of transcriptional factors that play a
critical role for the transcriptional initiation of inflammatory genes.
Our inability to precisely model such a cascade of events using
elementary kinetic steps makes indirect response models (IDR)
appealing. Indirect response models have been widely used in
pharmacokinetic/pharmacodynamic models simulating the phys-
iological response of a system exposed to an external signal or
perturbation [51]. Thus we propose to model the effect of LPS on
the transcriptional response level using the basic principles of an
Indirect Response Model (IDR) [52,53].
Of critical importance in analyzing dynamic systems is the
identification of the state space that characterizes the behavior
(response) of the system. To address this challenge, we recently
developed a computational methodology that allows us to capture
an elementary set of responses that describe the trajectory of
systemic inflammation in human blood leukocytes when exposed
to endotoxin stimulus [24,25]. Such responses are maximally
affected by the endotoxin stimulus and include the pro-
inflammatory response that consists of the early increased
expression of cytokines and chemokines; the anti-inflammatory
response which is assumed to serve as the immunoregulatory arm
of the host defense system and ultimately the energetic response
that involves the decreased expression of genes that participate in
cellular bio-energetic processes. We integrated these responses into
a mathematical model using the basic principles of an Indirect
Response Model (IDR) that bridges the extracellular signal (LPS)
with the downstream activation of the major transcriptional
responses. The model consists of eight (8) variables that include: (i)
the inflammatory instigator (LPS), (ii) the endotoxin signaling free
protein receptor (R, TLR4), (iii) the mRNA of TLR4 (mRNA,R),
(iv) the formed complex (LPSR), (v) the active signaling complex
(DR
*) and the essential transcriptional responses (vi) pro-
inflammation (P), (vii) anti-inflammation (A) and (viii) the energetic
Figure 13. Explore the effect of corticosteroids at multiple drug doses initiated at t=1 hr and continued for 6 hr after the
endotoxin challenge priming the production rate of IL10 signaling (A component). The effect of corticosteroids towards A signaling is
illustrated by the solid arrow. Solid lines characterize a resolution in the progression of systemic inflammation whereas dashed and dotted lines
correspond to lower drug doses that cannot sufficiently reverse the progression rate of an aberrant inflammation. All the active signals, DR(N)norm,
have been normalized with respect to the lowest drug dose, D0=20 ng/mL.
doi:10.1371/journal.pone.0004706.g013
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succinctly presented in Eq. (1) as it follows:
dLPS
dt
~klps,1:LPS: 1{LPS ðÞ {klps,2:LPS a ðÞ
dR
dt
~ksyn:mRNA,Rzk2: LPSR ðÞ {k1:LPS:R{ksyn:Rb ðÞ
dmRNA,R
dt
~Kin,mRNA,R: 1zHmRNA,DR 
  
{Kout,mRNA,R:mRNA,R c ðÞ
d LPSR ðÞ
dt
~k1:LPS:R{k3: LPSR ðÞ {k2 LPSR ðÞ d ðÞ
dDR 
dt
~k3:LPSR
A
{k4:DR zkc: DR  ½ 
5
1z DR  ½ 
5
 !
e ðÞ
dP
dt
~
Kin,P
A
: 1zHP,DR 
   : 1zHP,E ðÞ {Kout,P:Pf ðÞ
dA
dt
~Kin,A: 1zHA,P ðÞ : 1zHA,E ðÞ {Kout,A:Ag ðÞ
dE
dt
~
Kin,E
A
: 1zHE,P ðÞ {Kout,E:Eh ðÞ
HP,DR ~KP,DR :DR  i ðÞ
HP,E~KP,E:Ej ðÞ
HA,P~KA,P:Pk ðÞ
HA,E~KA,E:El ðÞ
HE,P~KE,P:Pm ðÞ
ð1Þ
A detailed description of the structure and the mathematical
representation of the aforementioned model is discussed in the
original analysis [26]. Meanwhile the appropriateness of such a
model was evaluated in a series of biologically relevant scenarios
and involve: (i) a self-limited inflammatory response where the
inflammatory stimulus is eliminated successfully, (ii) a persistent
infectious response where the inflammatory instigator is not
cleared from the system accounting for an aberrant inflammatory
response and finally (iii) a persistent non-infectious response that
can be elicited in response to an overload of the pathogen-derived
endotoxin. In addition to this, the potential of the model was
demonstrated by evaluating rapid endotoxin tolerance as well as
potentiating effects.
Developing an NFkB dependent indirect response model
of inflammation
In order to introduce a finer level of detail in our computational
model of inflammation we wish to deconvolute and interpret
mechanistically the combined signal DR*. In the original model,
DR* represent the event activating the transcription of the
proinflammatory response (P) which in turn initiates the
inflammatory response. As such, DR* is the signal activating,
i.e., transcriptionally regulating, the expression of the pro-
inflammatory genes. Thus, the mechanistic equivalent of DR*
would be the signaling cascade that activates pro-inflammatory
transcription factors controlling the expression of the pro-
inflammatory genes. Although a large family of transcription
factors is known to be involved in inflammation, we focus on a
particular family, NFkB, for two reasons. First, the nuclear factor
kB family is known to be a major player in the inflammatory
response [54] and as such it has been widely studied as a major
contributor. Second, the fact the NFkB plays an important role has
led to the development of numerous, independent, modeling
approaches in order to quantify the expected response of its
signaling cascade [33]. Therefore, we introduce the NFkB signal
transduction cascade as the prototypical module for initiating and
controlling the expression of pro-inflammatory genes.
Numerous signaling molecules and reactions participate in the
NFkB signaling pathway [33]. However, sensitivity analysis [55]
demonstrated that the activity of NFkB is maximally modulated by
a reduced set of basis signaling molecules (IKK, IKBa and NFkB).
As such [56] proposed a minimal model of NFkB that accounts for
the propensity of oscillations in the dynamic behavior of NF-kB
activity. However, instead of simulating the kinase activity as a
constant parameter and incorporating saturation degradation rates
as discussed in [56], we propose to model IKK as a transient
signal. Qualitatively, the dynamic IKK activity corresponds to its
intracellular concentration and it serves as the ‘‘input signal’’ for
the subsequent activation of NF-kB signaling module, Eq. (2).
dIKK
dt
~k3: LPSR ðÞ = 1zIkBa ðÞ
{k4:IKKzP: IKK2
1zIKK2
  
a ðÞ
dNFkBn
dt
~
kNFkB,1:IKK: 1{NFkBn ðÞ
1zIkBa ðÞ
{kNFkB,2:NFkBn:IkBa b ðÞ
dmRNAIkBa
dt
~Kin,IkBa: 1zkIkBa,1:NFkBn ðÞ
{Kout,IkBa:mRNAIkBa c ðÞ
ð2Þ
Thus the cellular surface complex (LPSR) induces the activation
of kinase activity (IKK) with a rate k3, while being eliminated with
a rate k4, (2a). The non-linear function of Hill-type, is an essential
functional form in order to achieve a bistability response in the
dynamics of the probed system [10,57,58,59]. In chronic
inflammatory diseases several cytokines might be responsible for
perpetuating and amplifying the inflammatory reaction through
the critical node (IKK) [36]. Therefore, we simulate such an
interaction by the presence of a positive feedback loop in (2a). The
dynamics of nuclear concentration of NF-kB are modeled in (2b)
assuming NFkBn as a percentage of its total cytoplasmic
concentration. Therefore, the term (1-NFkBn) denotes the
available free cytoplasmic concentration of NF-kB and in this
study the nuclear concentration (NFkBn) and nuclear activity are
used interchangeably. The import rate of cytoplasmic NF-kB into
the nucleus depends on the availability of its free cytoplasmic
concentration (1-NFkBn) stimulated by the kinase activity (IKK).
However, its degradation rate depends on the presence of its
primary inhibitor (IkBa) as the latter retrieves nuclear concentra-
tions of NFkB by forming an inactive complex in the cytoplasmic
region [60]. The dynamics of the gene transcript of IKBa
(mRNA,IKBa), (2c), are characterized by a zero order production
rate (Kin,IkBa) and a first order degradation rate (Kout,IkBa) which is
stimulated by NFkB [36].
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translation of its gene transcript (mRNA,IkBa) and it degrades at a
rate kI,2 which is stimulated by the kinase activity (IKK). Based on
the premise that IkBa forms a complex with the available
cytoplasmic NF-kB mathematically we expressed is as the product
(1-NFkBn) IkBa. From the modeling point of view, in order to
achieve a zero steady state for the protein inhibitor IkBa we need
the additional negative term 2kI,1.
dIkBa
dt
~kI,1:mRNAIkBa
{kI,2: 1zIKK ðÞ : 1{NFkBn ðÞ :IkBa{kI,1
ð3Þ
The dynamics of the gene transcript of the endotoxin signaling
receptor (mRNA,R) are described by a zero order production rate
(Kin,mRNA,R) and a first order degradation rate (Kout,mRNA,R), (4a).
d mRNA,R ðÞ
dt
~Kin,mRNA,R: 1zHP,R ðÞ
{Kout,mRNA,R:mRNA,R a ðÞ
HP,R~kP,R:Pb ðÞ
ð4Þ
We test the hypothesis that the pro-inflammatory signaling
indirectly stimulates the transcriptional activation of endotoxin
receptor (TLR4); which quantitatively is expressed by the linear
function (HP,R), (4b). Recently, there is research effort to elucidate
the unknown mechanism that drives the regulation of TLR4
expression [61] and research findings [62] support the potential
role of pro-inflammatory cytokines to up-regulate the TLR
expression.
At the transcriptional response level, instead of assuming the
active signaling complex, DR
* of Eq. (1f) to manifest the effect of
LPS on the cellular response level, herein we assume that the
nuclear activity of NF-kB (NFkBn) serves as the ‘‘active signal’’ that
indirectly stimulates the production rate of the essential pro-
inflammatory response (P), Eq. (5a).
dP
dt
~Kin,P: 1zHP,NFkBn ðÞ : 1zHP,E ðÞ =A{Kout,P:Pa ðÞ
HP,NFkBn~kP,1:NFkBn b ðÞ
HP,E~kP,2:Ec ðÞ
ð5Þ
Mathematically the stimulation of the nuclear activity NFkBn is
expressed by the linear function (HP,NFkBn), (5b) and downstream
of the pro-inflammatory response we preserve the structure of the
elements that constitute the anti-inflammatory and the energetic
response the same as shown in Eq. (1). For example, the energetic
response variable will be responsible for more pronounced
inflammation and therefore stimulates the pro-inflammatory
response (HP, E), (5c). The anti-inflammatory signaling component
is assumed to inhibit the production rate of the pro-inflammatory
transcriptional signature, (5a). The transcriptional dynamics of
anti-inflammation (A) and the energetic response (E) are modeled
on the same manner as discussed in Eq. (1). The integrated NF-kB
dependent indirect response model is presented in Eq. (6):
dLPS
dt
~klps,1:LPS: 1{LPS ðÞ {klps,2:LPS
dR
dt
~ksyn:mRNA,Rzk2: LPSR ðÞ {k1:LPS:R{ksyn:R
d LPSR ðÞ
dr
~k1:LPS:R{k3: LPSR ðÞ {k2: LPSR ðÞ
d mRNA,R ðÞ
dt
~Kin,mRNA,R: 1zHP,R ðÞ
{Kout,mRNA,R:mRNA,R
dIKK
dt
~k3: LPSR ðÞ = 1zIkBa ðÞ {k4:IKKzP: IKK2
1zIKK2
  
dNFkBn
dt
~
kNFkB,1:IKK: 1{NFkBn ðÞ
1zIkBa ðÞ
{kNFkB,2:NFkBn:IkBa
dmRNAIkBa
dt
~Kin,IkBa: 1zkIkBa,1:NFkBn ðÞ
{Kout,IkBa:mRNAIkBa
dIkBa
dt
~kI,1:mRNAIkBa
{kI,2: 1zIKK ðÞ : 1{NFkBn ðÞ :IkBa{kI,1
dP
dt
~Kin,P: 1zHP,NFkBn ðÞ : 1zHP,E ðÞ =A{Kout,P:P
dA
dt
~Kin,A: 1zHA,P ðÞ : 1zHA,E ðÞ {Kout,A:A
dE
dt
~Kin,E: 1zHE,P ðÞ =A{Kout,E:E
HP,R~kP,R:P
HNFkBn~kP,1:NFkBn
HP,E~kP,2:E
HA,P~kA,1:P
HA,E~kA,E:E
HE,P~kE,P:P
ð6Þ
Two major differences exist between the model in Eq. (1) and
the proposed NF-kB dependent indirect response model, Eq. (6).
First, the ‘‘translation’’ of the active signaling complex (DR
*) into
biologically relevant signaling compartments; namely involving the
activation of NFkB signaling module. Such a ‘‘translation’’ allows
us to simulate the positive interaction between the pro-inflamma-
tion and the intracellular signaling (IKK). Second, in (1) the
variable DR
* is assumed to be the convoluted signal that
propagates the LPS signaling initiating the transcriptional
synthesis of both the pro-inflammatory response (P) and the
mRNA of TLR4 (mRNA,R). However, in model (6) the
elucidation of DR
* to the NFkB activity limits the potential
structure of the model. That is to say NFkB is a pro-inflammatory
transcription factor and it is not involved in the transcriptional
regulation of the gene that encodes for the protein TLR4. On the
other hand, based on literature evidence we support the potential
role of pro-inflammatory signaling in mediating the transcriptional
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in the extended structure of the model, Eq. (6). The proposed NF-
kB dependent indirect response model is schematically illustrated
in Figure 1 shedding insight on the interactions of the elements
that constitute the inflammatory response. It offers us ‘‘realistic’’
handles on evaluating the effectiveness of various intervention
strategies that modulate the intrinsic dynamics of the system
opening areas amenable to the design of effective treatment
schedules [23]. In the present study we aim at exploring in silico the
pharmacodynamic effect of particular immunomodulatory agents
– corticosteroids - in modulating the progression of an unresolved
inflammatory response
Modeling Corticosteroid Interventions
The progression of a disease involves the perturbation in the
intrinsic dynamics of a system from its homeostasis [14]. The
presence of a disturbance (stimulus) initiates complex interaction of
components at multiple scales (genetic, molecular, cellular level).
The administration of a drug aims at modulating the progression
of the disease by interfering with either individual molecules or
signaling pathways. As such, we will explore means of modulating
the activity of NFkB through the use of corticosteroids Developing
mechanistic models of inflammation allows us to both characterize
the non-linear inflammatory trajectory under various ‘‘what-if’’
scenarios and importantly to evaluate the effectiveness of drug-
based treatment strategies that modulate the dynamics of the
system. Integrating the cellular mechanism of drug action on
disease progression models sheds insight on the better character-
ization of their pharmacodynamic effect against the disease status.
In the present study, we consider corticosteroids as the means
for controlling (modulating) the inflammatory state. One of the key
aspects is the integration of the opposing effect of two crucial
signaling pathways: one associated with the transcriptional
dynamics that are elicited in response to endotoxin stimulus
(LPS) and one related to the genomic signaling of exogenous
corticosteroids. Such a modeling approach allows us to explore the
pharmacodynamic effect of corticosteroids against inflammation
exploring various modes of action.
Significant prior research efforts have attempted to elucidate the
mechanisms driving corticosteroid activity [63,64,65,66,67,
68,69,70] Such studies simulate the pharmacogenomic effect of
glucocorticoids at the transcriptional level taking their mechanistic
(signaling) action into account [71,72] and mathematically is
expressed by Eq. (7) [72].
D~C1:e{l1tzC2:e{l2t a ðÞ
dRm
dt
~ksyn Rm: 1{
DR N ðÞ
IC50 RmzDR N ðÞ
  
{kdeg:Rm b ðÞ
dGR
dt
~ksyn R:RmzRf:kre:DR N ðÞ
{kon:D:GR{kdgr R:GR c ðÞ
dDR
dt
~kon:D:GR{kT:DR d ðÞ
dDR N ðÞ
dt
~kT:DR{kre:DR N ðÞ e ðÞ
ð7Þ
In essence the model as shown in Eq. (7) captures the
essential steps of the cellular signaling of steroids which include:
(i) the binding of the steroid drug (D) to its cytosolic receptor
(GR), (ii) the subsequent formation of the drug-receptor complex
(DR) (iii) the translocation of the cytosolic complex to the
nucleus (DR(N)) which alters the transcriptional machinery
activating or repressing numerous genes and finally (iv) the
autoregulation of the gene transcript of the glucocorticoid
receptor (Rm).
The drug disposition is modeled via a bi-exponential kinetic
model, (7a) and the plasma concentration of the drug (D) is
mathematically expressed by a kinetic model with Ci and li to be
the coefficients of intercepts and slopes [69,72]. The dynamics of
the gene transcript of the corticosteroid drug (Rm), (7b), are
characterized by a zero production rate (ksyn_Rm) and a first order
degradation rate (kdeg). The active drug-receptor complex (DR(N))
exerts an inhibitory effect towards the mRNA of the glucocorticoid
receptor. The parameter IC50_Rm denotes the concentration of the
nuclear drug-receptor complex DR(N) at which the synthesis rate
of the receptor drops at 50% of its baseline value. The dynamics of
the free cytosolic receptor density, GR, is modeled in (7c) where
ksyn_R is the synthesis rate of receptor that stems from its
transcription, Rf is the fraction of the drug that is recycled, kre is
the parameter that shows the recycling of drug from the nucleus to
the cytosol and kon is a parameter associated with the drug-
receptor binding. In addition to this, kdgr_R is the degradation rate
of the receptor (GR). The formed cytosolic complex (DR), (7d),
depends upon the binding interaction kon of the ligand (D) with its
receptor (GR) and on its translocation rate kT to the nucleus.
Therefore, the translocation of the drug-receptor complex to the
nucleus accounts for the nuclear receptor complex DR(N), (7e),
which is the active complex that mediates the transcriptional
induction of various genes.
Effectively, in [52] the model in Eq. (7) simulates in rat liver
the effect of plasma concentration of a corticosteroid drug after a
single intravenous administration of 50 mg/kg. The model
parameters are estimated based on available experimental data
and the qualitative structure of the integrated inflammatory
model with the active corticosteroid intervention envelope is
presented in Figure 6. We observe that the interaction of the
corticosteroid drug (D) with its receptor (GR) mediates the
activation of the nuclear drug-receptor complex (DR(N)). This
complex serves as the ‘‘active signal’’ that induces transcriptional
alterations suppressing the mRNA of the glucocorticoid receptor
(Rm) which drives downstream the reduced cytosolic receptor
density.
Given, therefore, a quantification of the dynamics of cortico-
steroids and putative modes of action of CS in regulating the
activity of NFkB [73,74] we test the hypothesis that corticosteroids
exert their immunosuppressive effect by enhancing the transcrip-
tional synthesis of NF-kB’s inhibitor IkBa (mRNA,IkBa). Such a
hypothesis does not imply that corticosteroids exert their anti-
inflammatory mechanisms via only this mechanism. It has
become increasingly evident [30] that corticosteroids manifest
their anti-inflammatory properties by various mechanisms that
involve (i) either up-regulation of critical anti-inflammatory
proteins, i.e. IkBa, IL-10; (ii) or increased expression of an
inhibitor to phospholipase A2 (annexin I) which subsequently
leads to reduced formation of both arachidonic acid and platelet-
activating factor as well as (ii) a disruption of the basal
transcriptional machinery that inhibits the transcriptional activity
of NFkB. In this study, due to our inability to model all the
mediators that may be affected by corticosteroids we opt to
simulate the effect manifested by exogenous corticosteroids
performing systematic perturbations on the primary inhibitor of
NFkB, i.e. IkB, as shown in Eq. (8).
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dt
~
Kin,IkBa: 1zkIkBa,1:NFkBn ðÞ : 1zDR N ðÞ norm
  
{Kout,IkBa:mRNAIkBa
ð8Þ
where DR(N)norm represents the normalized DR(N) signal that
numerically ranges between (0,1) for a given drug dose. The
reason for such normalization stems from the fact that the aim of
this study is to provide a qualitative understanding about how the
dynamics of a host undergoing an inflammatory response are
modulated due to the corticosteroid intervention envelope.
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